Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX6171 in Age Associated Memory Impairment
NCT00691808Phase 2Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Feb 2008
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LX6171 in Age-associated memory impairment (AAMI) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Number of Participants Who Were Exposed to LX6171 at 28 days, Number of Subjects Reporting at Least One Adverse Event (AE) at 28 days and 2 more. Started Feb 2008; status: completed.
02
Drugs
LX6171
03
Conditions
Age-associated memory impairment (AAMI)
Beyond the preview
Go deeper on NCT00691808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691808.